Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abandoned drugs
Idoxifene
Другие языки:

    Idoxifene

    Подписчиков: 0, рейтинг: 0
    Idoxifene
    Idoxifene.svg
    Clinical data
    Other names CB-7432, SB-223030; Pyrrolidino-4-iodotamoxifen; 4-Iodopyrrolidinotamoxifen
    Routes of
    administration    		 Oral
    Pharmacokinetic data
    Elimination half-life Acute: 15 hours
    Chronic: 23 days
    Identifiers
    • 1-[2-[4-[(E)-1-(4-iodophenyl)-2-phenylbut-1-enyl]phenoxy]ethyl]pyrrolidine
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    KEGG
    ChEMBL
    CompTox Dashboard (EPA)
    Chemical and physical data
    Formula C28H30INO
    Molar mass 523.458 g·mol−1
    3D model (JSmol)
    • CC/C(=C(/C1=CC=C(C=C1)OCCN2CCCC2)\C3=CC=C(C=C3)I)/C4=CC=CC=C4
    • InChI=1S/C28H30INO/c1-2-27(22-8-4-3-5-9-22)28(23-10-14-25(29)15-11-23)24-12-16-26(17-13-24)31-21-20-30-18-6-7-19-30/h3-5,8-17H,2,6-7,18-21H2,1H3/b28-27-
    • Key:JJKOTMDDZAJTGQ-DQSJHHFOSA-N

    Idoxifene (INN, USAN, BAN) (former developmental code names CB-7432, SB-223030), also known as pyrrolidino-4-iodotamoxifen, is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group which was under development for the treatment of breast cancer and postmenopausal osteoporosis but was never marketed. It reached phase III clinical trials for postmenopausal osteoporosis and phase II clinical trials for breast cancer before development was discontinued in 1999 due to insufficient effectiveness in both cases.

    Chemistry

    Synthesis

    A large-scale chemical synthesis of idoxifene has been devised.

    External links




    Новое сообщение